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ABSTRACT 
Objective: To perform a systematic review and meta-analysis of studies investigating 
neurocognition in euthymic youths with bipolar disorder (BD) compared to healthy controls 
(HCs). 
Method: A systematic literature search was conducted in the PubMed/MEDLINE, 
PsycINFO, and EMBASE databases from inception up until March 23rd, 2016 for original 
peer-reviewed articles that investigated neurocognition in euthymic youths with BD 
compared to HCs. Effect sizes (ES) for individual tests were extracted. In addition, results 
were grouped according to cognitive domain. This review complied with the PRISMA 
statement. 
Results: 24 studies met inclusion criteria (N=1,146; 510 with BD). Overall, euthymic youths 
with BD were significantly impaired in verbal learning, verbal memory, working memory, 
visual learning, and visual memory with moderate to large ESs (Hedge’s g between 0.76 to 
0.99); significant impairments were not observed for attention/vigilance, reasoning and 
problem solving, and/or processing speed. Heterogeneity was moderate to large (I2 ≥ 50%) 
for most ES estimates. Differences in the definition of euthymia across studies explained the 
heterogeneity in the ES estimate for verbal learning and memory. We also found evidence for 
other potential sources of heterogeneity in several ES estimates including co-occurring 
attention-deficit/hyperactivity disorder (ADHD) and anxiety disorders, and the use of 
medications. In addition, the use of different neuropsychological tests appeared to contribute 
to heterogeneity of some estimates (e.g. attention/vigilance domain). 
Conclusion: Euthymic youths with BD exhibit significant cognitive dysfunction 
encompassing verbal learning and memory, working memory, and/or visual learning and 
memory domains. These data indicate that for a subset of individuals with BD, 
neurodevelopmental factors may contribute to cognitive dysfunction.   
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INTRODUCTION 
Evidence that bipolar disorder (BD) in adults is associated with broad neurocognitive 
impairment across several domains has accumulated in the literature in the past two 
decades.1,2 These findings have been synthesized in several meta-analyses3-5 that confirmed 
that euthymic adults with BD have most pronounced deficits (of moderate to large effect 
sizes) in attention, verbal memory, and executive function. Furthermore, a large individual 
patient meta-analysis confirmed that euthymic adults with BD exhibit cognitive impairment 
encompassing several domains.6 Nevertheless, this effort found smaller effect sizes in 
comparison to previous meta-analyses, perhaps due to a more accurate adjustment for 
potential confounders and the inclusion of unpublished datasets.6  
 BD has been increasingly diagnosed in pediatric age groups, with an estimated pooled 
prevalence rate of 1.8% in general population surveys.7 In addition, a significant proportion 
of adults with BD have onset of illness before the age of 18.8,9 Patients with early onset of 
illness may have worse outcomes including but not limited to fewer days of euthymia and 
greater functional impairment, which may hamper academic achievements.9-12  
 Cognitive impairment is thought to be a main mediator of disability and functional 
impairment in BD.2,13 Evidence indicates that cognitive impairment may be evident in first-
episode BD.14 A previous systematic review15 and two meta-analyses16,17 suggested that 
cognitive impairment in pediatric BD is mainly present in verbal learning, processing speed, 
and executive function domain. However, these analyses included individuals with BD 
during different mood states, and the largest available meta-analysis included 12 unique 
studies (N=374).17 Since the publication of those previous systematic reviews and meta-
analyses, several new original studies provided data on cognitive function in euthymic youths 
with BD.18-21 However, different clinical characteristics of samples may lead to heterogeneity 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
across studies. For example, evidence suggests that the use of medications21 and co-occurring 
mental disorders (notably attention-deficit/hyperactivity disorder [ADHD])22 may impact 
cognitive function in youths with BD.  
 Therefore, a systematic review and meta-analysis of studies that had assessed 
cognitive impairment in euthymic youths with BD compared to healthy controls was 
performed. We expected a high degree of heterogeneity across studies in part due to 
differences in sample characteristics (for example, duration of illness, comorbid ADHD, and 
medication status) as well as differences in neuropsychological measures.23 Thus, we also 
aimed to explore potential sources of heterogeneity.  
METHOD 
This study comprised a meta-analysis of studies comparing neurocognitive function in 
euthymic youths with BD to healthy controls. We complied with the Preferred Reported 
Items for Systematic Reviews and Meta-analysis (PRISMA) statement, and followed an a 
priori defined yet unpublished protocol.24 The literature search, title/abstract screening, final 
decision on eligibility after full-text review, and data extraction were independently 
performed by at least two investigators (L.R.O., A.M.O.V., and H.L.K.). Disagreements were 
resolved through consensus. If a consensus could not be achieved, the decision was made 
independently by a third investigator (C.A.K.).    
Search Strategy 
A systematic search was conducted in the EMBASE, PubMed/MEDLINE, and 
PsycInfo databases from inception up until March 23rd, 2016. The detailed search strings used 
in this review are presented in the supplementary online material that accompanies the online 
version of this article. This search strategy was augmented through tracking the citation of 
included articles in Google Scholar.25 
Study Selection 
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We included original peer-reviewed articles published in English, Danish, Spanish, 
Portuguese, French, or German. Eligible studies had to include youth (i.e., aged ≤ 18 years 
old) participants meeting either DSM26 or International Classification of Diseases (ICD)27 
criteria for BD, and a comparison sample of healthy controls (HCs). In addition, the diagnosis 
of BD had to be established through a validated structured/semi-structured diagnostic 
interview. For this systematic review, we considered studies that had measured cognitive 
domains according to standard tests and/or batteries (vide infra). Neurocognitive function has 
been heuristically subdivided into “hot” (i.e., emotion-laden) and “cold” (i.e., emotion-
independent) cognition.28, 29 For the purposes of this systematic review, we had solely 
included studies measuring “cold” cognition because this dimension has been more 
consistently related to clinical outcomes (e.g., functional status).15 We applied the following 
exclusion criteria: (1) studies that did not diagnose BD by means of a structured diagnostic 
interview; (2) meeting abstracts; (3) studies published in other languages (i.e., not specified 
above); (4) studies that included participants from other age groups (unless data were 
reported separately for youths); (5) investigations that included participants with BD in an 
acute mood episode or otherwise clinically unstable; (6) studies that did not include an HC 
group.  
Data Extraction 
We extracted the means ± standard deviation (SD) of each neuropsychological test 
score or the appropriate reported effect size estimate. In addition to meta-analysis of 
individual tests, we also grouped tests according to cognitive domains based on the National 
Institute of Mental Health-MATRICS (Measurement and Treatment Research to Improve 
Outcome in Schizophrenia) with slight modifications due to available data from tests not 
included in this initiative (Table S1, available online).30, 31 We also extracted the following 
data whenever available: (1) First author; (2) Publication Year; (3) sample size; (4) gender 
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distribution (% Females); (5) mean illness duration (years); (6) definition of euthymia 
considered in each study32; (7) the medications in use (categorized as lithium, 
anticonvulsants, and antipsychotics); and (8) overall intelligence (mean IQ scores).  Evidence 
points to a high prevalence of comorbid psychiatric conditions (up to 90%) among youths 
with BD.33-35 In addition, some reports indicate that a significant proportion of youths with 
BD may have comorbid ADHD in clinical settings.36,37 Therefore, we extracted data on the 
frequency of comorbid mental disorders in each included study; we considered cognitive data 
for participants with BD and no comorbid mental disorders whenever a study provided these 
data. 
Statistical Analysis 
Because studies used different measurement methods, standardized mean difference 
estimates of difference in test scores were used as effect size (ES) estimates utilizing Hedge’s 
g, which provides an unbiased ES adjusted for small sample sizes.38 The 95% CI was also 
computed.39 An ES of 0.2 was considered low, 0.5 moderate, and 0.8 large.40 The ES of each 
cognitive domain represents the average of the ES estimates derived from each of its 
pertinent neuropsychological measures.41 We also calculated a global cognition measure by 
averaging the ES from each cognitive domain, when three or more domains were assessed in 
the same study.41 This composite measure aimed to provide a broad estimate of overall 
cognitive function. At least three independent datasets had to be available to estimate a 
summary ES (for both individual tests and cognitive domains). 
 Studies with statistically non-significant (i.e. negative) results are less likely than 
studies with positive results of being published.42,43 To account for significant publication 
bias, we inspected a funnel plot graph for asymmetry and calculated the Egger’s test.44 
 We assessed the heterogeneity across studies using the Cochran Q test, a weighted 
sum of the squares of the deviations of individual study ES estimates from the overall 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
6 
 
estimate. In addition, heterogeneity across studies was quantified with the I2 statistic, which 
in brief indicates the percentage of total variation across several studies due to heterogeneity, 
and it is considered moderate when between 50-75%, and high when greater than 75%.45 We 
anticipated a high degree of heterogeneity. Therefore, we pooled ES from several studies 
according to the inverse variance method of accounting for random effects. Random-effects 
modelling assumes a genuine diversity across studies and incorporates a between-study 
variance into the calculations.39  
 We explored potential sources of heterogeneity across studies in each cognitive 
domain with either subgroup or random-effects meta-regression analyses. We considered the 
following variables in univariate meta-regression analyses: sample size, mean age of BD 
group, mean age of the HC group, differences in mean age (BD group minus HC group), % of 
females in the BD group, % of females in the HC group, difference in % of females (BD 
group minus HC group), mean IQ of the BD group, mean IQ of the HC group, difference in 
mean IQ (BD group minus HC group), % of participants on lithium, % of participants on 
anticonvulsants, % of participants on antipsychotics. Studies were weighted in such a way 
that investigations with more precise parameters (indicated by sample size and 95% CI) had 
more influence in meta-regression analyses.46 A covariate was investigated in meta-
regression analyses when at least five independent datasets provided data on the potential 
moderator. We performed a subgroup analysis based on the criteria of euthymia employed in 
each study. For the purposes of these analyses, we classified each study based on a stringent 
definition of euthymia (i.e., euthymia as pre-defined based on scores in standard symptom 
rating instruments). A non-stringent definition of euthymia was considered when at least one 
of the following were met: (1) mean scores of the Young Mania Rating Scale (YMRS)47 < 12 
and the Children’s Depression Rating Scale-Revised (CDRS-R)48 ≤ 28 or (2) euthymia was 
established by a clinical assessment. We electronically contacted the corresponding author of 
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manuscripts in at least two separate occasions if there was uncertainty regarding the 
definition of euthymia. In addition, we performed subgroup analyses on the following 
variables: (1) presence of comorbid ADHD in the BD group (Yes/No); (2) presence of co-
morbid anxiety disorders in the BD group (Yes/No); (3) history of psychotic symptoms; (4) 
on lithium use; (5) on antipsychotic use; and (6) on anticonvulsant use. We estimated the 
power of each summary ES estimate across a hypothetical range of ‘true’ ESs with a method 
developed by Hedges and Pigott.49  
All analyses were conducted with the metan package in Stata MP software version 
14.0 (Stata-Corp, College Station, TX, USA). Statistical significance was considered at an 
alpha level of 0.05. 
RESULTS 
Following the removal of duplicates, the title/abstracts of 1,909 unique references 
were screened for eligibility. A total of 1,675 references were excluded, while 234 full-text 
were retrieved and screened for eligibility. Finally, 24 original studies met inclusion 
criteria.18-22, 50-68 Figure 1 provides the PRISMA flowchart for study selection.  
Characteristics of Included Studies 
This systematic review and meta-analysis included 24 studies that provided data from 
1,146 participants (510 youths with BD and 636 HCs). Across the 24 included studies, there 
were no differences in age (BD group:  13.62 ± 3.76; HC group: 13.29 ± 3.22, P = .12) and 
IQ scores (BD group: 103.58 ± 15.76; HC group: 104.64 ± 24.32, P = .44) between groups, 
while 12 studies followed an age- and gender-matched design. Table S2 (available online) 
provides a description of included studies.  
Global Cognition 
 Seven studies provided evidence that youths with BD are significantly impaired in 
global cognition (Table 1). There was no evidence of publication bias. Heterogeneity was 
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large (I2 = 85%). Figure 2A provides the forest plot of this meta-analysis. Mean age of the 
BD group appeared to moderate this ES estimate, with older participants being more 
cognitively impaired. The frequency of current use of lithium and antipsychotics also 
moderated this outcome, where use of these medications appeared to impair this domain 
(Table S3, available online). Subgroup analyses found that global cognition was impaired in 
studies that included youths with BD and comorbid anxiety disorders (with low 
heterogeneity) but not in those that included participants without comorbid anxiety disorders. 
In addition, deficits in this domain were significant in studies that included youths with BD 
and co-morbid ADHD (with low heterogeneity) but not in those that included youths with BD 
without comorbid ADHD. Lastly, impairment in this domain was observed only in studies 
that considered the stringent criteria for euthymia albeit with high heterogeneity (Table S4, 
available online).   
<Please insert Table 1 here> 
Attention and Vigilance 
Overall, attention and vigilance were not significantly impaired in youths with BD 
compared to HCs (Table 1; Figure 3). However, a moderate degree of heterogeneity was 
observed for this ES estimate. Meta-regression analyses suggested that the mean age and the 
percentage of female participants in the HC moderated this outcome. Furthermore, the 
frequency of current use of anticonvulsants and antipsychotics emerged as moderators of this 
outcome, with evidence suggesting that the use of these drugs could impair this cognitive 
domain (Table S3, available online). Subgroup analyses suggest that this cognitive domain 
could be impaired in youths with BD in studies that considered the stringent criteria for 
euthymia (with low heterogeneity) but not in studies that considered other definitions (Table 
S4, available online).  Furthermore, impairment in this domain was observed in studies that 
included youths with BD and comorbid anxiety disorders, but not studies that included only 
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participants with BD without this comorbidity (Table S4, available online). Participants with 
BD were slightly impaired in the hit reaction time and the omission scores of the Continuous 
Performance Test-II (CPT-II).69 These results suggest that youths with BD may have 
difficulties with sustained attention. Interestingly, heterogeneity for this ES estimates were 
low. In addition, results of the Go/Nogo tasks seem to confirm that youths with BD have 
deficient impulse control (Table 1).    
Reasoning and Problem Solving 
Youths with BD were not significantly impaired in reasoning and problem solving 
(Table 1; Figure 4). However, heterogeneity for this ES estimate was high. Meta-regression 
analyses indicated that the frequency of use of antipsychotics and anticonvulsants moderated 
this ES, with data suggesting that the use of these drugs could impair this domain (Table S3, 
available online).  
Verbal Learning and Memory 
Youths with BD were significantly impaired in verbal learning and memory compared 
to HCs, with a moderate ES (Figure 2B). Heterogeneity was large (Table 1). In studies that 
considered a stringent definition for euthymia, heterogeneity was low and a significant 
impairment was observed, whereas no significant effect was verified in studies that used 
other definitions of euthymia. Furthermore, impairment in this domain was observed in 
studies that included youths with BD and co-occurring ADHD (with low heterogeneity) but 
not in studies that included solely youths with BD without this comorbidity (Table S4, 
available online).  
Working Memory 
Our results indicate that pediatric BD is associated with large impairments in working 
memory (Table 1; Figure 2C). Heterogeneity was moderate (I2=62%). However, it is 
noteworthy that results obtained with the Wechsler Intelligence Scale for Children (WISC) 
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digit span forward test confirmed this finding, with low heterogeneity (Table 1). 
Heterogeneity was large in studies that included youths with BD and comorbid anxiety 
disorders, but low in studies that included youths with BD without this comorbidity (Table 
S4, available online).  
Speed of Processing 
Just three studies provided extractable data for the speed of processing domain.22, 51, 65 
Evidence suggests that youths with BD are not significantly impaired in this domain (Table 1; 
Figure 5). 
Visual Learning and Memory 
Youths with BD were significantly impaired in visual learning and memory (Table 1; 
Figure 2D) with a moderate to large ES (Hedge’s g = 0.78). In addition, heterogeneity was 
low. 
Verbal Fluency 
A single small study (N=40) investigated this cognitive domain by means of the 
Benton Controlled Oral Association Test, phonemic Fluency FAS (COWAT).21,70 No 
significant difference between euthymic adolescents with BD and age- and gender-matched 
controls was observed. 
Power Analysis  
A post hoc power analysis indicate that the meta-analysis of the attention and 
vigilance domain had adequate power to reject the null hypothesis considering a medium 
‘true’ effect size, whereas the summary ES estimates for reasoning and problem solving and 
speed of processing had a low power to reject the null hypothesis considering a medium 
‘true’ effect size (Table S5, available online). 
DISCUSSION 
This meta-analysis provides evidence that euthymic pediatric patients with BD have 
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significant cognitive impairment of moderate-to-large ES when compared to HCs in the 
global cognition score, as well as in verbal and visual learning and memory and working 
memory domains. These results are consistent with previous meta-analyses conducted in 
euthymic adults with BD that provided evidence that these domains are impaired when 
compared to HCs.3,5,71 However, available evidence indicates that other cognitive domains 
are similarly impaired in euthymic adults with BD, including attention/vigilance, reasoning 
and problem solving, and processing speed.5 These results suggest that cognitive dysfunction 
may be broader in adults compared to youths with BD.  
Two recent meta-analyses indicate that global cognitive deficits are already evident in 
first-episode BD.14, 72 However, these meta-analyses included only studies of adult samples. 
Our results provide evidence that cognitive dysfunction encompassing several cognitive 
domains could already be evident in euthymic youths with BD.  
Some limitations of our work deserve discussion. First, heterogeneity for several ES 
estimates was high. We explored potential sources of heterogeneity across studies with 
standard meta-regression and subgroup analyses. Results from meta-regressions should be 
cautiously interpreted due to the possibility of type I error.73  We found evidence that the use 
of medications contributed to the heterogeneity of most ES estimates. In addition, meta-
regression analyses suggested that the frequency of use of lithium and antipsychotics may 
have a detrimental effect upon global cognition. Few studies have investigated the cognitive 
effects of those medications in youths with BD. A previous observational study found that 
mood stabilizers may adversely impact certain neurocognitive domains, while atypical 
antipsychotics had no significant effect on neurocognition.74 Clearly our findings should be 
interpreted cautiously due to the inclusion of few studies in those analyses, and future 
prospective studies are needed to investigate the impact of mood stabilizing medications on 
cognition in pediatric samples with BD. In addition, it is possible that the effects observed in 
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our exploratory analyses could be confounded by other clinical variable (e.g., youths with 
more severe BD could more likely require the use of mood stabilizing medications). We 
could not control for these covariates (e.g., length of illness, number of affective episodes) 
due to the fact that included studies did not consistently provide data. It is worthy to note that 
the definition of euthymia has varied across studies, which might have influenced some 
findings of our analyses. For example, most of the heterogeneity in the ES estimate of the 
verbal learning and memory domain appeared to be explained by the criterion of euthymia 
adopted by each study, with low heterogeneity for studies that used a more stringent 
definition of euthymia. Furthermore, our analyses suggest that co-morbid ADHD or anxiety 
disorders contributed to the heterogeneity of several estimates, and we found some 
indications that these co-occurring disorders may negatively impact some neurocognitive 
domains (e.g. global cognition and attention/vigilance). These suggestive findings add to 
emerging evidence that indicates that these comorbidities may have a deleterious impact on 
the course of pediatric BD.75  Lastly, neuropsychological measures tapping into the cognitive 
domains varied across studies. This aspect may have contributed to heterogeneity of some 
estimates. For instance, whilst no significant differences emerged in the attention/vigilance 
domain, individual test meta-analyses (in the CPT-II and Go/Nogo tasks) suggested that 
youths with BD do display impaired attention and impulse control regulation. 
Two previous quantitative analyses have included youths with BD across the 
spectrum of mood states.16,17 Our meta-analysis was restricted to the inclusion of euthymic 
pediatric participants with BD, thus allowing a more precise estimation of trait-related 
cognitive deficits. Furthermore, this updated meta-analysis included twice the number of 
studies compared to the largest previous meta-analysis.17 This previous meta-analysis found 
broader cognitive impairments (with medium ES estimates) in youths with BD encompassing 
general cognitive ability, attention, executive control, working memory, visuospatial skills, 
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verbal fluency, verbal learning and memory, and visual memory domains.17 However, the 
inclusion of participants in different mood states might have confounded their results as 
suggested by an exploratory moderator analysis performed by the authors.17 Thus, an 
important strength of our work rests in the provision of the best possible synthesis of 
available evidence.       
 Cognitive impairment has emerged as a consistent target for drug and psychological 
treatments for BD.76-78 Our results provide a rationale for testing the impact of those 
interventions in youths with BD. In addition, the impact of cognitive dysfunction in 
functioning among youths with BD remains largely unknown although a controlled study 
indicates that executive deficits may impair academic achievement in youths with BD.74 
 This meta-analysis has several research implications. First, our results indicate that a 
better standardization of neuropsychological assessments across studies investigating 
neurocognitive dysfunction in youths with BD is necessary. Our results may provide useful 
indications for this purpose. For example, our individual test meta-analysis suggests that the 
WISC-digit span forward79 might provide a sensitive and consistent (with low heterogeneity) 
measure of working memory in youths with BD. Second, future studies should provide a 
better description and control for potential confounding variables. Third, more studies are 
necessary to investigate cognitive dysfunction encompassing the processing speed and verbal 
fluency domains in euthymic youths with BD. Fourth, available evidence does not 
consistently indicate that adult patients with early-onset BD could be more cognitively 
impaired after adjustment for potential confounders.80,81 Therefore, prospective studies are 
warranted to precisely determine the course of cognitive deficits in youths with BD. Finally, 
future studies should control for the presence of co-occurring ADHD as well as compare 
cognitive dysfunction in youths with BD to youths with ADHD without comorbid mood 
disorders. 
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Clinical guidance 
• This meta-analysis indicates that euthymic youths with bipolar disorder exhibit 
impairments in global cognition, verbal and visual learning and memory, and working 
memory compared to healthy controls with moderate to large effect sizes. 
• Neuropsychological assessments have varied across studies. In addition, the definition 
of euthymia was not consistent in included investigations. The impact of some illness 
variables (e.g. illness duration and number of previous affective episodes) on 
cognitive dysfunction in pediatric BD remains incompletely elucidated. 
• Our findings indicate that cognitive dysfunction may be a viable therapeutic target for 
pharmacological and psychological intervention in euthymic youths with BD. 
FIGURE LEGENDS 
FIGURE 1. Preferred Reported Items for Systematic Reviews and Meta-analysis (PRISMA) 
flowchart of included studies. Note: MATRICs = Measurement and Treatment Research to 
Improve Outcome in Schizophrenia. 
FIGURE 2. Forest plots for effect size estimates (and 95% CI) for (A) global cognition; (B) 
verbal learning and memory; (C) working memory; and (D) visual learning and memory in 
euthymic youths with bipolar disorder (BD) compared to healthy controls (HCs).  
FIGURE 3. Forest plots for effect size estimates (and 95% CIs) for the attention and 
vigilance cognitive domain. Note: BD = bipolar disorder. 
FIGURE 4. Forest plots for effect size estimates (and 95% CIs) for the reasoning and 
problem solving cognitive domain. Note: BD = bipolar disorder. 
FIGURE 5. Forest plots for effect size estimates (and 95% CIs) for the speed of processing 
cognitive domain. Note: BD = bipolar disorder. 
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Table 1. Cognitive Differences Between Youths With Bipolar Disorder and Healthy Controls 
Domain/Testa N 
studies 
N 
cases 
N 
healthy 
controls 
Hedges's 
g 
95% CI Overall 
P-value Q 
I2 
(%) 
Small-
study 
effectsb Lower Upper 
Global cognitionc 7 132 210 0.78 0.16 1.41 .014 38.63d 85 0.349 
 
       
 
  
Attention/vigilance 12 254 349 0.18 -0.06 0.43 .144 22.11d 50 0.734 
Continuous Performance Test-II 
 
  
    
 
  Comissions 4 68 196 -0.14 -0.51 0.23 .462 5.15 42 0.644 
Hit reaction time 4 67 148 0.48 0.09 0.86 .017 4.74 37 0.660 
Omissions 5 92 173 0.41 0.15 0.67 .002 3.68 0 0.528 
Go-Nogo tasks 
 
  
    
 
  Accuracy go (%) 3 76 63 0.03 -0.31 0.38 .854 2.17 8 0.223 
Go reaction time (ms) 3 76 63 -0.36 -0.69 -0.02 .036 0.11 0 0.920 
Inhibit delay (ms) 3 76 63 -0.53 -0.87 -0.19 .002 0.25 0 0.334 
No-go reaction time (ms) 3 88 64 0.20 -0.12 0.53 .216 1.81 0 0.621 
 
          
Reasoning and problem solving 12 224 301 0.43 -0.12 0.97 .125 91.14d 88 0.889 
Wisconsin Card Sorting Test (WCST) 
 
  
    
 
  Conceptual level responses 4 81 155 -0.55 -0.83 -0.27 < .001 1.99 0 0.554 
Failure to maintain set 3 57 52 0.63 -0.18 1.44 .127 8.47d 76 0.391 
N of categories 6 101 126 -0.42 -0.69 -0.15 .002 3.71 0 0.538 
Non-perseverative errors 6 100 103 -0.20 -0.83 0.44 .543 25.00d 80 0.222 
Perseverative errors 11 203 280 0.30 -0.34 0.95 .360 105.53d 91 0.751 
Total errors 3 54 52 0.32 -0.60 1.25 .494 11.15d 82 0.071 
 
      
 
 
  
Verbal learning and memory 7 150 251 0.76 0.29 1.22 .001 24.93d 76 0.355 
California Verbal Learning Test for Children (CVLT-C) 
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Long delay free recall 3 85 105 -0.90 -1.65 -0.15 .019 10.53d 81 0.419 
Recognition 3 89 154 -1.13 -2.40 0.15 .084 33.60d 94 0.357 
Short delay free recall 3 85 105 -0.89 -1.37 -0.42 < .001 4.26 53 0.468 
TOMAL Facial Memory 3 49 56 -0.68 -1.39 0.03 .062 6.15d 67 0.394 
 
       
 
  
Working memory 8 159 274 0.99 0.64 1.35 < .001 18.29d 62 0.764 
WISC Digit-span Forward 4 77 106 -0.79 -1.10 -0.48 < .001 1.60 0 0.452 
        
 
  
Speed of processing 3 65 91 1.27 -0.12 2.65 .074 27.51d 93 0.269 
 
       
 
  
Visual learning and memory 4 64 71 0.78 0.43 1.13 < .001 2.79 0 0.226 
Note: Statistically significant results are in bold. TOMAL = Test of Memory and Learning; WAIS = Wechsler Adult Intelligence Scale;  
WISC = Wechsler Intelligence Scale for Children. 
a
 Effect sizes for the individual test measures are in the original test direction (i.e, an effect size larger than zero indicates that the measure is increased in cases, 
while an effect size smaller than zero indicates that the measure is decreased). Domains and global cognition positive effect size measures indicate cognitive 
impairment in cases, and are computed by averaging individual test measures. 
b
 P-value In Egger’s test for publication bias. 
c
 Global cognition score was calculated only in studies that evaluated 3 or more cognitive domains. 
d
 P < .05 
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Records after duplicates removed 
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(n = 210)
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23 = Not euthymic
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13 = Authors contacted, no 
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